Meeting
2020 ASCO Virtual Scientific Program
Evaluation of minimal residual disease in relapsed/refractory multiple myeloma patients treated with venetoclax or placebo in combination with bortezomib and dexamethasone: BELLINI study analyses.
Authors
Philippe Moreau
Hematology Department, CHU Nantes, Nantes, France
Philippe Moreau , Simon J. Harrison , Michele Cavo , Javier de La Rubia , Rakesh Popat , Vania Hungria , Hans Salwender , Kenshi Suzuki , Inho Kim , Andrew Spencer , Michael O'Dwyer , Wan-Jen Hong , Muhammad Jalaluddin , Xiaoqing Yang , James Michael Pauff , Paulo Cesar Maciag , Jeremy A. Ross , Shaji Kumar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Plasma Cell Disorders
Clinical Trial Registration Number
NCT02755597
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8547)
DOI
10.1200/JCO.2020.38.15_suppl.8547
Abstract #
8547
Poster Bd #
447
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
First Author: Shaji Kumar
Poster
2020 ASCO Virtual Scientific Program
Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, +/- bortezomib, in patients with relapsed/refractory multiple myeloma.
First Author: Jonathan L. Kaufman
Poster
2019 ASCO Annual Meeting
ECOG-ACRIN EAA172: Phase 1/2 study of daratumumab, bortezomib, dexamethasone (DVd) with or without venetoclax in relapsed/refractory multiple myeloma (RRMM) with assessment for t(11;14) status.
First Author: Michael A. Thompson
Poster
2018 ASCO Annual Meeting
A phase 1/2, multicenter, dose-escalation and expansion study of combination therapy with venetoclax, daratumumab, and dexamethasone (with and without bortezomib) in subjects with relapsed or refractory multiple myeloma.
First Author: Orlando Bueno